• Mashup Score: 0
    Thea Pharma launches Iyuzeh in US - 7 month(s) ago

    Thea Pharma has launched Iyuzeh in the U.S. for the treatment of primary open-angle glaucoma or ocular hypertension.

    Source: www.healio.com
    Categories: Latest Headlines, Ophthalmology
    Tweet Tweets with this article
    • Profile photo of Healio_OSN
      Healio_OSN

      🚨Thea Pharma has launched Iyuzeh in the U.S. for the treatment of primary open-angle #glaucoma or #ocularhypertension. 🚨 Read the full press release below: #OcularSurgeryNews #MedNews https://t.co/37RXUv7wAG

  • Mashup Score: 0
    Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943 | Vincerx Pharma - 8 month(s) ago

    Phase 1 trial enrolling patients with relapsed/refractory AML, MDS and B-cell ALL PALO ALTO, Calif. , Sept. 14, 2023 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through

    Source: investors.vincerx.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of AML_Hub
      AML_Hub

      🚨 NEWS 🚨 First patient dosed in a phase I study of VIP943, a novel CD123 antibody-drug conjugate, to assess the safety, pharmacokinetics/pharmacodynamics, and preliminary efficacy in patients with R/R AML, MDS, or B-cell ALL. https://t.co/ptucEyk7lz. #AMLsm #leusm #MedNews https://t.co/XmDlyf0uVw

  • Mashup Score: 1
    Vididencel received fast track designation from the U.S. FDA - 8 month(s) ago

    On September 8, 2023, vididencel, an off-the-shelf, intradermal vaccine, received fast track designation from the FDA for the treatment of patients with AML in CR with residual disease.

    Source: aml-hub.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of AML_Hub
      AML_Hub

      🚨 NEWS 🚨 Vididencel, an off-the-shelf, intradermal vaccine, receives fast track designation from the @US_FDA for the treatment of patients with AML in CR with residual disease. 👉 https://t.co/0kG8vKk0kY. #leusm #MedNews https://t.co/hNpGjaDodd

  • Mashup Score: 2
    Bexmarilimab granted orphan drug designation by the U.S. FDA - 8 month(s) ago

    On August 29, 2023, the U.S. FDA granted orphan drug designation to bexmarilimab, a first-in-class humanized monoclonal antibody, for the treatment of patients with AML.

    Source: aml-hub.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of AML_Hub
      AML_Hub

      🚨 NEWS 🚨 @US_FDA grants orphan drug designation to bexmarilimab, a first-in-class anti-Clever-1 humanized monoclonal antibody and macrophage reprogrammer, for the treatment of patients with AML. 👉 https://t.co/fo8flBnMcw #AMLsm #leusm #MedNews https://t.co/a72xhqCP5C

  • Mashup Score: 2
    Vincerx Pharma Announces FDA Clearance of IND for VIP943 | Vincerx Pharma - 8 month(s) ago

    Phase 1 trial expected to begin in early Q4 2023 VIP943 is Vincerx’ first candidate from next-generation ADC platform and its second IND clearance within 8 months, highlighting Vincerx’s development and regulatory expertise PALO ALTO, Calif. , Aug. 22, 2023 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc.

    Source: investors.vincerx.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of AML_Hub
      AML_Hub

      🚨 NEWS 🚨 @US_FDA gives clearance to an Investigational New Drug application to initiate the phase I clinical trial of VIP943, a CD123-targeting antibody-drug conjugate, for the treatment of patients with advanced AML and MDS. https://t.co/ccDytDKdTW. #leusm #AMLsm #MedNews https://t.co/xvLVu4jMfi

  • Mashup Score: 2
    BITT Announces FDA Acceptance of IND for TNFR2 Antibody - 9 month(s) ago

    The FDA has cleared BITT’s IND application for a Phase I trial of BITT2101 (anti-TNFR2) in patients with relapsed/refractory Non-Hodgkin’s lymphomas

    Source: www.businesswire.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of lymphomahub
      lymphomahub

      🚨 NEWS 🚨 @US_FDA has cleared an Investigational New Drug application for a phase I trial of anti-TNFR2 in patients with R/R NHL. Elevated levels of soluble TNFR2 were reported in patients with NHL; TNFR2 is linked to disease progression. https://t.co/KQx3q8nhiS #lymsm #mednews https://t.co/VNKiyh0da7

Load More